retatrutide clinical trials retatrutide mechanism Substack Series 3 of 6: – The Next Frontier in Longevity and Metabolic Health What Are the Key Benefits

doi: 10.1016/J.DSX.2024.103067 47 LiuQK

Retatrutide engages GLP-1R, GIPR, and GCGR with differential but meaningful potency at each site, producing a composite pharmacodynamic signal not achievable with single or dual agonists

Proper hydration (water plus electrolytes) improves digestive motility and reduces constipation severity

Of greater concern are potential risks from combination use: Hypoglycaemia risk: Retatrutide enhances insulin secretion in a glucose-dependent manner, which carries a low intrinsic hypoglycaemia risk when used alone

Every participant in the 12mg group lost at least 5% of body weight

The current batch (Lot RET10-2162026, 99.914% purity) is downloadable from the product page and independently verifiable online